Volume : 13, Issue : 08, August – 2026
Title:
ARTIFICIAL INTELLIGENCE AND PRECISION MEDICINE IN PARKINSON’S DISEASE: EMERGING DIAGNOSTIC AND THERAPEUTIC APPROACHES
Authors :
Manisha, Soma Sekhar Pulamarasetti*, Omkar Rai, Karan Gupta, Shivlal Yadav
Abstract :
Background: Parkinson’s disease (PD) is heterogeneous, both clinically, genetically and neuropathologically, which presents ongoing challenges for conventional syndromic clinical diagnostic criteria and uniform treatments. Recent advances in biofluid biomarkers, high-resolution neuroimaging and artificial intelligence (AI) have provided frameworks to reclassify PD on an objective biological basis and personalize therapeutic interventions 4 .
Objective: To critically synthesize recent advances in AI-driven diagnostic modalities, biological disease staging frameworks, biofluid biomarkers, genotype-targeted therapeutics and adaptive clinical trial designs in PD7.
Data Sources: A search was conducted in PubMed, MEDLINE, Scopus, Web of Science and other major biomedical literature databases for studies published mostly between 2018 and 20244.
Review Methods: Evidence from clinical trials, neuroimaging studies, digital sensor evaluations, biofluid biomarker investigations, and regulatory science guidelines was reviewed using a comparative synthesis approach2 .
Key Findings: The biological definition of PD, formalized by the Neuronal Alpha-Synuclein Disease Integrated Staging System (NSD-ISS), bases disease classification on in vivo seeded aggregation of alpha-synuclein () and dopaminergic neurodegeneration ()4. Deep learning models applied to single-photon emission computed tomography (SPECT) and magnetic resonance imaging (MRI) yield diagnostic classification accuracies in the range of 88%–99%5. Non-invasive digital devices such as radio-wave nocturnal breathing sensors and video-based kinetic software allow continuous surveillance at home6. Biomarker-enriched clinical trials8 are being driven by targeted therapeutics, including small-molecule and antisense oligonucleotide agents targeting LRRK2 and GBA1 mutations. But the implementation of these algorithms in practice is still held back by algorithmic overfitting, a lack of validation in diverse non-European cohorts and regulatory concerns around continuous machine learning updates13.
Conclusion: The combination of biological staging and AI-enabled digital phenotyping provides a scalable paradigm for early detection and targeted therapeutic selection in PD4. Standardized analytical pipelines, harmonized regulatory oversight, and adaptive clinical trial designs10 are needed for clinical translation.
Keywords: Parkinson Disease, Artificial Intelligence, Precision Medicine, Biomarkers, Machine Learning, Neurodegenerative Diseases
Cite This Article:
Please cite this article in press Soma Sekhar P et al., Artificial Intelligence And Precision Medicine In Parkinson’s Disease: Emerging Diagnostic And Therapeutic Approaches. Indo Am. J. P. Sci, 2026; 13(08).
REFERENCES:
1. Toward a Biological Definition of Neuronal and Glial Synucleinopathies – DigitalCommons@TMC, https://digitalcommons.library.tmc.edu/cgi/viewcontent.cgi?article=7409&context=uthgsbs_docs
2. New Diagnostic and Staging Framework Applied to Established PD in the BioFIND Cohort, https://pmc.ncbi.nlm.nih.gov/articles/PMC12060982/
3. Toward Personalized Medicine Approaches for Parkinson Disease Using Digital Technologies – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC10568402/
4. Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC11419206/
5. An Automated Diagnosis of Parkinson’s Disease from MRI Scans Based on Enhanced Residual Dense Network with Attention Mechanism – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12343449/
6. Artificial intelligence-enabled detection and assessment of Parkinson’s disease using nocturnal breathing signals – PubMed, https://pubmed.ncbi.nlm.nih.gov/35995955/
7. Utilizing Intraindividual Cognitive Variability to Predict Early Neuronal Synuclein Disease Progression – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC13142576/
8. Recent advances in targeting LRRK2 for Parkinson’s disease treatment – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12235878/
9. AI-Driven Advances in Parkinson’s Disease Neurosurgery: Enhancing Patient Selection, Trial Efficiency, and Therapeutic Outcomes – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12110375/
10. John D. Loeser Award Lecture: Size does matter, but it isn’t everything: the challenge of modest treatment effects in chronic pain clinical trials – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC7434212/
11. Application of new biologic disease criteria for synucleinopathies to the systemic synuclein sampling study cohort – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC11972316/
12. Blood-Based α-Synuclein Biomarkers in Parkinson’s Disease: Molecular Diversity, Analytical Advances and Clinical Translation – MDPI, https://www.mdpi.com/1422-0067/27/14/6254
13. Creative Commons Attribution 4.0 International (CC BY 4.0) https, https://mdsoar.org/bitstreams/0cfee260-f8cd-4b30-b803-833ee49b8c0d/download
14. An improved method for diagnosis of Parkinson’s disease using deep learning models enhanced with metaheuristic algorithm – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC11194992/
15. Hybrid deep learning novel framework for classification of parkinson’s disease – PMC – NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC12996281/
16. Remote AI Screening for Parkinson’s Disease: A Multimodal, Cross-Setting Validation Study – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12270200/
17. LRRK2-targeting antisense oligonucleotide in Parkinson’s disease: a phase 1 randomized controlled trial – PubMed, https://pubmed.ncbi.nlm.nih.gov/41876647/
18. FOXO family and neurodegenerative diseases: Mechanisms of action and therapeutic potential – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC13235356/
19. Parkinson’s disease detection using inceptionV3: A Deep learning approach – PMC – NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC12090310/
20. Most prominent challenges in translational neuroscience and strategic solutions to bridge the gaps: Perspectives from an editorial board interrogation – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12373390/
21. Biological definitions of synucleinopathies should be anchored in clinical trajectories and encompass the complex biology of the disease – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC13347495/
22. Machine learning for Parkinson’s disease: a comprehensive review of datasets, algorithms, and challenges – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12217022/
23. Applications of machine learning for computer-aided diagnosis of Parkinson’s disease: progress and benchmark case study – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12397128/
24. New diagnostic and staging framework applied to established PD in the BioFIND cohort, https://pmc.ncbi.nlm.nih.gov/articles/PMC12137746/
25. Neuroimaging Methods to Map In Vivo Changes of OXPHOS and Oxidative Stress in Neurodegenerative Disorders – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC9266616/
26. Biomarkers and neuroimaging markers in Parkinson’s disease – PMC – NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC12487944/
27. Synergistic blood-based diagnostic value of AP3B1 and BMPR2 in Parkinson’s disease, https://pmc.ncbi.nlm.nih.gov/articles/PMC12569060/
28. Neuroimaging and fluid biomarkers in Parkinson’s disease in an era of targeted interventions – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC11226684/
29. Current potential biomarkers for Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis: review of literature – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12885010/
30. Machine learning integration of serial blood biomarkers enhances cognitive decline prediction in early Parkinson’s disease – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC13057232/
31. Advances in Circulating Biomarkers for Neurodegenerative Diseases, Traumatic Brain Injuries, and Central Nervous System Tumors – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12187502/
32. Pathways to personalized medicine—Embracing heterogeneity for progress in clinical therapeutics research in Alzheimer’s disease – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC11485305/
33. A survey of detection of Parkinson’s disease using artificial intelligence models with multiple modalities and various data preprocessing techniques – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC11657906/
34. Classification of Parkinson’s disease by deep learning on midbrain MRI – PMC – NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC11369979/
35. Parkinson’s image detection and classification based on deep learning – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC11270773/
36. Artificial Intelligence That Changes Clinical Neurology Practice: Translating Algorithms Into Actionable Care – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC13364534/
37. Applications of Artificial Intelligence in Neurological Voice Disorders – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12753207/
38. From Diagnosis to Treatment: A Comprehensive Review of Biomarkers and Therapeutic Advances in Parkinson’s Disease – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC11863227/
39. Voice-Based Early Diagnosis of Parkinson’s Disease Using Spectrogram Features and AI Models – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12562018/
40. NCT03976349 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson’s Disease | ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT03976349
41. Peripheral immunochemical considerations in Parkinson disease: sources, targets and crosstalk mechanisms – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC13217690/
42. CRISPR and Artificial Intelligence in Neuroregeneration: Closed-Loop Strategies for Precision Medicine, Spinal Cord Repair, and Adaptive Neuro-Oncology – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12524701/
43. Molecular Biomarkers of Neurodegenerative Disorders: A Practical Guide to Their Appropriate Use and Interpretation in Clinical Practice – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC11049959/
Volume : 13, Issue : 08, August – 2026
Title:
EVALUATION OF THE ANTIASTHMATIC ACTIVITY OF AZIMA TETRACANTHA LAM LEAVES IN ANIMAL MODELS
Authors :
Dr. Alivelu Samala, Dr. N. Raghunandan, Mohammed Simran Begum
Abstract :
Asthma is a chronic disease that affects approximately 300 million people worldwide. Although wide range of drug is available, the relief is mainly symptomatic and short lived. Azima tetracantha leaves, is traditionally used to treat asthma. However, the scientific data on anti-asthmatic and anti- Cholinergic of this plant has got little attention. An attempt has been based on ethanolic extract of leaves of Azima tetracantha shown a tremendous effect on asthma when comparative study was done with normal and treated group. The anti-asthmatic activity of a 50% aqueous ethanol extract of dried and fresh leaves, and the volatile and fixed oils of Azima tetracantha was evaluated against histamine and acetylcholine-induced preconvulsive dyspnea (PCD) in guinea pigs fasted for 24 h were exposed to an atomized fine mist of 2% histamine dihydrochloride aerosol (dissolved in normal saline) using nebulizer at a pressure of 300 mm Hg in the histamine chamber (24 x 14 x 24 cm, made of perplex glass). Guinea pigs exposed to histamine aerosol showed progressive signs of difficulty in breathing leading to convulsions, asphyxia and death. The time until signs of convulsion appeared is called Preconvulsion time (PCD). By observation experience was gained so that the Preconvulsion time can be judged accurately. As soon as PCD commenced, animals were removed from the chamber and placed in fresh air to recover. In the present experiments the criterion used was time for onset of dysponea and percent protection was calculated. Those animals which developed typical histamine asthma within 3 min were selected out three days prior to the experiment and were given habituation practice to restrain them in the histamine chamber. They were divided in groups Mepyramine (8 mg/kg) and polyherbal formulation (300 mg/kg) were administered intraperitonially 30 min prior to exposure. Animals, which did not develop typical asthma within 6 minutes, were taken as protected.
Keywords: Antiasthamatic, Azima tetracantha, Histamine-induced model and Acetylcholine induced model.
Cite This Article:
Please cite this article in press Alivelu Samala et al., Evaluation Of The Antiasthmatic Activity Of Azima Tetracantha Lam Leaves In Animal Models. Indo Am. J. P. Sci, 2026; 13(08).
REFERENCES:
1. Prasad R, Lawnia RD, Gupta MR. (2009). Role of herbs in the management of asthma. Pharmacog Rev, 3(6), 247-257.
2. Aggarwal AN, Chaudhry K, Chhabra SK, D’Souza GA, Gupta D, Jindal SK, Katiyar SK, Kumar R, Shah B, Vijayan VK. (2009). Prevalence and Risk Factors for Bronchial Asthma in Indian Adults: A Multicentre Study. Indian J Chest Dis Allied Sci, 48, 13-22.
3. Tattersfield AE, Knox AJ, Britton JR, Hall IP. (2002). Asthma. Lancet, 360,1313-1322.
4. Stevens DA, Schwartz HJ, Lee JY. (2000). A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med, 342, 756- 762.
5. Conron M, Beynon HLC.(2000). Churg-Strauss syndrome. Thorax, 55, 870- 877.
6. Szczeklik A, Nizankowska E, Duplaga M. (2000). On behalf of the AIANE Investigators. Natural history of aspirin-induced asthma. Eur Respir J,16, 432.
7. Saunders. (2005). Asthma. In: Homer A, Boushey JrMD, David B, Corry MD, John V, Fahy MD, Esteban G, Burchard MD, Prescott G, Woodruff MD, et al. ed. Mason: Murray & Nadel’s Textbook of Respiratory Medicine, 4th ed., Elsevier.
8. Yawn BP. (2008). Factors accounting for asthma variability, achieving optimal symptom control for individual patients. Prim Care Resp J, 17(3), 138–147.
9. Martinez FD. (2007). Genes, environments, development and asthma: A reappraisal. Eur Resp J, 29(1), 179–184.
10. Tattersfield AE, Knox AJ, Britton JR, Hall IP. (2002). Asthma. Lancet, 360,1313-1322.
11. Dodge RR, Burrows B. (1980). The prevalence and incidence of asthma and asthma-like symptoms in a general population sample. Am Rev Respir Dis, 122, 567-575.
12. Jenkins MA, Hopper JL, Bowes G, Carlin JB, Flander LB, Giles GG. (1994).Factors in childhood as predictors of asthma in adult life. BMJ, 309, 90-93.
13. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. (1998). A 15-year follow up study of ventilatory function in adults with asthma. N Engl J Med, 339, 1194-1200.
14. Stolley PD, Schinnar R. (1978). Association between asthma mortality and isoproterenol aerosols: A review. Prev Med, 7, 519-538.
15. Adkinson NF, Bochner BS, Busse WW, Holgate St, Lemanske RF, Simons FR. (2008). Adverse Reactions to Foods: Respiratory Food Hypersensitivity Reactions. Middleton’s Allergy Principles & Practice.Elsevier.
16. Jenkins C, Costello J, Hodge L. (2004). Systematic review of prevalence of aspirin-induced asthma and its implications for clinical practice. Br Med J, 328(7437), 434.
17. Mery B, Nowak PH. (2002). Indoor swimming pools, water chlorination and respiratory health, Eu Resp J, 5, 790.
18. Chen E, Miller GE. (2007). Stress and inflammation in exacerbations of asthma. Brain Behav Immun, 21(8), 993–999.
19. Ippets B, Guilbert TW. (2009). Managing asthma in children: Part 1: Making the diagnosis, assessing severity, Consult Ped, 8(5).
20. Ayres JG, Clark TJH. (1983). Alcohol drinks and asthma: A survey. Br J Dis Chest, 77, 370-375.
21. Wilson N, Vickers H, Taylor G, Silverman M. (1982). Objective test for food sensitivity in asthmatic children: Increased bronchial reactivity after cola drinks. BMJ, 284, 1226-1228.
22. Kogevinas M, Anto JM, Sunyer J, Tobias A, Kromhout H, Burney P. (1999).For the European Community Respiratory Health Survey Study Group.Occupational asthma in Europe and other industrialized areas: A population-based study. Lancet, 353, 1750-1754.
23. Chan-Yeung M, Malo JL. (1994). Aetiological agents in occupational asthma. Eur Respir J, 7, 346-371.
24. Szentivanyi A. (1968). The beta adrenergic theory of the atopic abnormality in asthma, J Allergy, 42, 203-232.
25. Richard L. (2006). In lasting tribute: Andor Szentivanyi, MD. J Allergy Clin Immunol, 117(1): 1-230.
26. Kowalak JP, Hughes AS. (2001). Professional Guide to Diseases, 7th ed. Springhouse publishing, Lippincott Williams & Wilkins.
27. Hogg JC. (1993). Pathology of asthma. J Allergy Clin Immunol, 92, 1-5.
28. Stolley PD, Schinnar R. (1978). Association between asthma mortality and isoproterenol aerosols: A review. Prev Med, 7, 519-538.
29. Kleijnen J, ter Riet G, Knipschild P. (1991). Acupuncture and asthma: A review of controlled trials. Thorax, 46, 799-802.
30. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. (2000). Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med, 343, 332-336.
31. Greening AP, Ind PW, Northfield M, Shaw G. (1994). Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet, 344, 219-224.
32. Blais L, Ernst P, Boivin JF, Suissa S. (1998). Inhaled corticosteroids and the prevention of readmission to hospital for asthma. Am J Respir Crit Care Med, 158, 126-132.
33. Pauwels RA, Lofdahl CG, Postma DS. (1997). For the Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med, 337, 1405-1411.
34. Cumming RG, Mitchell P, Leeder SR. (1997). Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med, 337, 8-14.
Volume : 13, Issue : 08, August – 2026
Title:
EVALUATION OF ANTIHYPERLIPIDEMIC ACTIVITY OF SAPINDUS EMARGINATUS IN RATS
Authors :
Chinthala Jamima*, Dr.R.narasimha Rao, Dr.N. Raghunandhan
Abstract :
Obesity and hyperlipidemia have become major disorders predominantly causing prevailing cardiovascular diseases and ultimately death. The prolonged use of anti-obesity drugs and statins for reducing obesity and blood lipid levels is leading toward adverse effects of kidneys and muscles, specifically rhabdomyolysis. The objective of this study is to evaluate potential of seeds of Sapindus emarginatus against hyperlipidemia. In this model of Hyperlipidemia, 30 adult male wistar rats (200-250gms) were evenly divided into 5 groups in both groups. Group-1 and Group-2 served as untreated and model controls respectively, while Group-3, 4 and 5 were the treatments groups which were simultaneously treated with standard, 100 and 200 mg/kg extract respectively along with High Fat Diet. On last day, blood samples for biochemical parameters, were obtained under inhaled diether anaesthesia. The outcomes of this study were expressed as mean standard error and data were evaluated by using analysis of variance followed by multiple comparisons. Oral administration of 100 mg/ kg and 200mg/kg body weight of Methanolic extract residual fraction of Moringa oleifera. Leaves exhibited a significant reduction (P < 0.01) in serum lipid parameters such as triglycerides, total cholesterol, low density lipoprotein (LDL), very LDL and increase in high density lipoprotein in hyperlipidemic rats when compared with hyperlipidemic control in both models. Our results demonstrated that Methanolic extract fraction of Sesbania grandiflora. Possessed significant antihyperlipidemic activity.
Keywords: Sesbania grandiflora, Cholesterol, LDL, triglycerides and antihyperlipidemic activity.
Cite This Article:
Please cite this article in press Chinthala Jamimaet al., Evaluation of Antihyperlipidemic activity of Sapindus Emarginatus in rats,, Indo Am. J. P. Sci, 2026; 13(08).
REFERENCES:
1. Amit G, Vandana S, Sidharth M. HYPERLIPIDEMIA: An Updated Review. Inter J of Biopharma & Toxicol Res 2011;1:81-89.
2. Virchow RP, Thrombose IG. In Gesammelte Abhandlungen zur Wissenschaftlichen Medicin. Frankfurt-am-Main, Meidinger Sohn & Company 1856, S 458-564.
3. Ankur rohilla, Nidhi Dagar, Seema Rohilla, Amarjeet Dahiya, Ashok Kushnoor. HYPERLIPIDEMIA- a deadly pathological condition. Inter J Curr Pharma Res 2012;4:15-18
4. Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med 1976;295:369-77.
5. Grundy SM, Vega GL. Hypertriglyceridemia: causes and relation to coronary heart disease – Semin. Thromb. Hemost 1988;14:249-64.
6. Dargel R. Lipoproteins and the etiopathogenesis of atherosclerosis. Zentralbl Allg Pathol 1989; 135: 501-504.